# OnCo record axicabtagene-ciloleucel (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/axicabtagene-ciloleucel/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "axicabtagene-ciloleucel" ;
  schema:name "Axicabtagene ciloleucel"@en ;
  schema:description "A CD19 CAR-T that cures about 40% of patients with large B-cell lymphoma who had failed everything, and beat transplant in second line."@en ;
  schema:url <https://onco.cc/drugs/axicabtagene-ciloleucel/> ;
  schema:dateModified "2026-09-04"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Axicabtagene_ciloleucel> ;
  owl:sameAs <http://www.wikidata.org/entity/Q30314851> ;
  schema:citation <https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Axicabtagene%20ciloleucel>, <https://doi.org/10.1038/s41591-020-1061-7>, <https://doi.org/10.1182/blood.2021010930>, <https://doi.org/10.1158/2159-8290.CD-15-1020> ;
  onco:status "approved" ;
  onco:modality "CAR-T (CD19)" ;
  schema:alternateName "Yescarta" ;
  onco:approval "US 2017: Relapsed/refractory large B-cell lymphoma ≥2 lines", "US 2022: Second-line LBCL refractory or relapsed within 12 months" ;
  onco:acceleratedApproval "US 2021-03-05: Treatment of adult patients with relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy" ;
  onco:cancers <https://onco.cc/cancers/dlbcl/>, <https://onco.cc/cancers/primary-mediastinal-b-cell-lymphoma/> ;
  onco:technologies <https://onco.cc/technologies/car-t/> ;
  onco:targets <https://onco.cc/targets/cd19/> ;
  onco:companies <https://onco.cc/companies/gilead/> ;
  onco:terms <https://onco.cc/terms/lymphoma-bio-antigen-escape/> ;
  onco:trials <https://onco.cc/trials/nct05371093/> .